Characterisation of the Ral GTPase inhibitor RBC8 in human and mouse platelets by Walsh, Tony G. et al.
                          Walsh, T. G., Wersäll, A., & Poole, A. W. (2019). Characterisation of the Ral
GTPase inhibitor RBC8 in human and mouse platelets. Cellular Signalling,
59, 34-40. https://doi.org/10.1016/j.cellsig.2019.03.015
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1016/j.cellsig.2019.03.015
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at DOI:
10.1016/j.cellsig.2019.03.015. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Contents lists available at ScienceDirect
Cellular Signalling
journal homepage: www.elsevier.com/locate/cellsig
Characterisation of the Ral GTPase inhibitor RBC8 in human and mouse
platelets
Tony G. Walsh⁎,1, Andreas Wersäll1, Alastair W. Poole
From the School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol BS8 1TD, United Kingdom
A R T I C L E I N F O
Keywords:
Platelets
Ral GTPase
Secretion
Human
Mouse
A B S T R A C T
The Ral GTPases, RalA and RalB, have been implicated in numerous cellular processes, but are most widely
known for having regulatory roles in exocytosis. Recently, we demonstrated that deletion of both Ral genes in a
platelet-speciﬁc mouse gene knockout caused a substantial defect in surface exposure of P-selectin, with only a
relatively weak defect in platelet dense granule secretion that did not alter platelet functional responses such as
aggregation or thrombus formation. We sought to investigate the function of Rals in human platelets using the
recently described Ral inhibitor, RBC8. Initial studies in human platelets conﬁrmed that RBC8 could eﬀectively
inhibit Ral GTPase activation, with an IC50 of 2.2 μM and 2.3 μM for RalA and RalB, respectively. Functional
studies using RBC8 revealed signiﬁcant, dose-dependent inhibition of platelet aggregation, secretion (α- and
dense granule), integrin activation and thrombus formation, while α-granule release of platelet factor 4, Ca2+
signalling or phosphatidylserine exposure were unaltered. Subsequent studies in RalAB-null mouse platelets
pretreated with RBC8 showed dose-dependent decreases in integrin activation and dense granule secretion, with
signiﬁcant inhibition of platelet aggregation and P-selectin exposure at 10 μM RBC8. This study strongly suggests
therefore that although RBC8 is useful as a Ral inhibitor in platelets, it is likely also to have oﬀ-target eﬀects in
the same concentration range as for Ral inhibition. So, whilst clearly useful as a Ral inhibitor, interpretation of
data needs to take this into account when assessing roles for Rals using RBC8.
1. Introduction
Platelets are essential regulators of haemostasis, limiting blood loss
following acute injury, while exacerbated platelet activity in diseased
blood vessels is causative of ischaemic tissue damage due to occlusive
thrombosis. These events are characterised by dynamic changes in
platelet activation responses, including actin cytoskeleton remodelling
(shape change and spreading), integrin activation (facilitating platelet
aggregation), granule secretion (lysosomes, dense and α-granules),
prostaglandin production (thromboxane A2) and phosphatidylserine
exposure (facilitating thrombin-mediated coagulation) [1,2]. These
functional responses are regulated by distinct signalling pathways
propagated from various glycoprotein (GP) receptors (GPVI, GPIb-IX-
V), G protein-coupled receptors (GPCRs – PAR1/4, TP, P2Y1/12) and
integrin complexes (αIIbβ3, α2β1) which converge into common sig-
nalling pathways [3]. Among a range of identiﬁed signalling molecules
important for platelet activation are the small GTPase proteins, in
particular Rap1A and Rap1B (Ras family) and Rac1, RhoA, RhoG and
Cdc42 (Rho family), which could represent suitable pharmacological
targets for antithrombotic therapies [4–6].
Ral GTPases (RalA and RalB) are ubiquitously expressed members of
the Ras subfamily of GTPases and are particularly abundant in the
brain, testes and platelets [7]. Besides Rap1A and 1B, which have in
excess of 100,000 copies/platelet, RalA and RalB are among the more
highly expressed Ras GTPase members with 3400 and 6800 copies/
platelet, respectively [8,9]. They target numerous eﬀectors including
Ral-binding protein 1 (RalBP1), phospholipase D and the exocyst
complex to regulate cell polarity, exocytosis, autophagy and various
cellular responses associated with tumorigenesis and metastasis
[10–14]. In platelets, Rals have been previously shown to be activated
in response to various agonists, dependent on rises in cytosolic Ca2+
[7]. A further study suggested a role for Rals in regulating platelet
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dense granule secretion in human platelets, which is consistent with
reports in other cell types [15,16]. We recently showed however a re-
stricted role for Rals in regulating exposure of P-selectin on the plasma
membrane of mouse platelets [17]. Conditional deletion of either RalA
or RalB in platelets showed no substantial alterations in P-selectin ex-
posure, however deletion of both RalA and RalB (double knockout,
DKO) in platelets produced a pronounced defect in this response. This
conﬁrmed a redundancy between Rals, which had been previously re-
ported [13]. However, the defect was unusual in that release of soluble
α-granule content, such as platelet factor 4 (PF4), was largely un-
altered. This suggested a speciﬁc and novel role for Rals, speciﬁcally in
the control of P-selectin exposure on the platelet surface.
Importantly, other aspects of platelet function (aggregation,
spreading, in vitro and in vivo thrombosis) important for haemostasis
and thrombosis were unaltered in Ral DKO platelets and mice. Beyond
haemostasis and thrombosis however, platelets have been implicated in
numerous pathophysiological processes, in which secreted biomole-
cules from platelet α-granules are likely to play major roles [18,19]. For
instance, platelet-expressed P-selectin is crucial in mediating platelet-
leukocyte/immune cell and platelet-endothelial cell interactions in-
volved in inﬂammatory responses [20]. Therefore, since we have shown
them to be critically selective for the regulation of surface expression of
P-selectin, platelet Ral GTPases may represent a possible candidate for
targeting inﬂammatory diseases in which platelets have well-estab-
lished roles in, in particular atherosclerosis and cancer [21,22]. We
recently showed that the platelet-speciﬁc RalAB DKO mice have de-
layed onset of clinical signs in an inﬂammatory bowel disease model
[17]. However, despite similarities in relative abundance of both Rals
between mouse and human platelets, it is still important to clarify if
Rals perform similar roles in human platelets, which could pave the
way for future therapeutic approaches targeting platelet P-selectin re-
lease [9,23].
The development of selective inhibitors targeting small GTPases has
posed signiﬁcant challenges for researchers. There is substantial inter-
ested in targeting these molecules, most notably in the ﬁeld of oncology
where the development of direct Ras inhibitors are often referred to as
the “Holy Grail” of cancer therapeutics [24]. Numerous targeting
strategies have been sought to overcome this, including the speciﬁc
targeting of downstream eﬀectors of Ras [25]. Being downstream of
Ras, RalA and RalB have gained increasing interest as potential targets
in the treatment of cancer, leading to the development of the ﬁrst
commercially available Ral inhibitor, RBC8 [26]. This non-competitive
compound binds to an allosteric site on GDP-bound Rals, locking them
in an inactive state, which blocks their interaction with the eﬀector
protein, Ral binding protein 1 (RalBP1). Importantly, RBC8 showed
selectivity over GTPases Ras and Rho, and functionally it could suppress
tumor xenograft growth in mice, which is consistent with a previous
publication describing redundant roles for RalA and RalB in tumor-
igenesis [13,26]. Based on our ﬁndings in RalAB DKO platelets, we
sought to investigate the role of Ral GTPases in human platelets using
RBC8 as a molecular tool to block Ral function, while utilising RalAB
DKO platelets to assess the speciﬁcity of RBC8 in similar functional
assays. We conﬁrm that RBC8 eﬀectively reduces RalA and RalB acti-
vation in human platelets, but the compound was able to inhibit also
functional responses that were not seen to be inhibited by gene deletion
in the DKO mouse. Furthermore, RBC8 inhibited various aspects of
platelet function in RalAB-null mouse platelets, suggesting RBC8 also
has oﬀ target activity in platelets, in the concentration range where Ral
is inhibited. We conclude therefore that, although clearly useful as a
reagent to eﬀectively inhibit RalA and RalB activity, in platelets at least
there are likely to be other targets for RBC8. So, whilst clearly useful as
a Ral inhibitor, interpretation of data needs to take this into account
when assessing roles for Rals in platelets using RBC8.
2. Materials and methods
2.1. Materials
RBC8 was provided as a generous gift from Prof. Theodorescu
(Cedars-Sinai, USA) and reconstituted in DMSO (used as vehicle con-
trol). Platelet agonists: Cross-linked collagen related peptide (CRP) was
purchased from Prof. Richard Farndale (University of Cambridge, UK),
adenosine diphosphate (ADP) and thrombin was from Sigma-Aldrich
(Poole, UK) and protease activated receptor activating peptide (PAR4-
AP) was from Peptide Synthetics (Hampshire, UK). For western blot-
ting, RalA (# 3526) and RalB (# 3523) antibodies were from Cell
Signalling Technology (New England Biolabs, Hitchin, UK) and BD
Biosciences (Oxford, UK, # 610222), and the Rap1 antibody (#sc-65)
was from Santa Cruz Biotechnology (Insight Biotechnology, Middlesex,
UK). Horseradish peroxidase (HRP)-conjugated secondary antibodies
were from Jackson Immunoresearch (Stratech Scientiﬁc, Glasgow, UK).
EDTA-free Protease inhibitors (# 11836170001) were from Roche
(West Sussex, UK). For human platelet ﬂow cytometry experiments:
FITC-conjugated PAC-1 (# 340507) and PE-conjugated CD62P/P-se-
lectin (# 561921) antibodies from BD Biosciences were used for mea-
suring integrin αIIbβ3 activation and α-granule secretion, respectively.
For mouse platelet ﬂow cytometry experiments: PE-conjugated JON/A
(# M023-2) and FITC-conjugated CD62P/P-selectin (# M130-1) anti-
bodies from Emfret Analytics (Eibelstadt, Germany) were used for
measuring integrin αIIbβ3 activation and α-granule secretion, respec-
tively. For mouse platelet-leukocyte aggregate studies, FITC-conjugated
CD41 antibody (# MCA2245F) was from Bio-Rad (Hertfordshire, UK)
and PE-conjugated CD45 antibody (# 103101) was supplied by
BioLegend (London, UK). DiOC6 iodide for labelling whole blood was
from Enzo Life Sciences (Exeter, UK, # ENZ-52303). Fura-2 AM (#
F1221) to measure intracellular calcium (Ca2+) and Alexa Fluor 488-
conjugated annexin V (# A13201) to measure phosphatidylserine (PS)
exposure, were from Molecular Probes™ (Thermo Fisher Scientiﬁc,
Loughborough, UK). Human PF4 DuoSet ELISA (# DY795) was pur-
chased from R&D Systems (Abingdon, UK). Unless stated, all other re-
agents were purchased from Sigma-Aldrich.
2.2. Human and mouse platelet isolation
Both human and animal studies were approved by the local research
ethics committee at the University of Bristol. For human platelet stu-
dies, informed consent was obtained from healthy, drug/anti-platelet
free volunteers in accordance with the declaration of Helsinki. Venous
blood was drawn into a syringe containing 4% trisodium citrate (1:9 v/
v) and platelets were prepared as previously described [27]. For mouse
platelet studies, conditional RalAB deﬁcient mice in the mega-
karyocyte-platelet lineage were generated using transgenic PF4-Cre
mice as previously described [17]. RalAﬂox/ﬂox:RalBﬂox/ﬂox mice that
were Cre− are herein referred to as wild-type (WT); RalAﬂox/ﬂox:-
RalBﬂox/ﬂox mice that were Cre+ are herein referred to as double
knockout (DKO). These mice were bred and maintained in accordance
with the UK Home Oﬃce regulations and Animals (Scientiﬁc Proce-
dures) Act of 1986 (PPL No: 300/3445 held by Prof. Alastair Poole).
Age- (8–24weeks) and sex-matched mice were used for all experiments.
Mice were euthanized by CO2 asphyxiation and blood was drawn from
the inferior vena cava into a syringe containing 4% trisodium citrate
(1:9 v/v). Washed mouse platelets were prepared as previously de-
scribed [28]. Both human and mouse platelets were allowed to recover
for at least 30min at 30 °C prior to experimentation. Pre-treatment of
whole blood/washed platelets with the Ral inhibitor, RBC8, or vehicle
control (0.2% DMSO) was for 15min prior to agonist addition.
2.3. Glutathione S-transferase (GST)-RalBP1 puriﬁcation
A pGEX4T3-GST-RalBP1 expression vector, containing amino acids
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397–518 of human RalBP1, was generated as previously described [7].
The vector was transformed in BL21(DE3)pLysS protease-free bacteria
(Agilent Technologies, CA, USA) and grown to log phase in lysogeny
broth media before induction with 0.2mM isopropyl β-D-1-thioga-
lactopyranoisde (IPTG) for 3 h at 30 °C. Bacteria were pelleted at
6000 rpm for 30min (4 °C) in a Sorvall RC 6 Plus centrifuge (Thermo
Fisher Scientiﬁc, SLA-1500 rotor) and lysed in 15mL of Phosphate-
buﬀered saline (PBS) lysis buﬀer (1 x PBS, 0.1% Triton X-100, 1mM
dithiothreitol (DTT), protease inhibitor tablet). The bacterial lysate was
freeze-thawed, then supplemented with 100 μg/mL lysozyme before
sonication, followed by lysate clariﬁcation at 12,000 rpm for 30min
(4 °C, Sorvall SS34 rotor). GST-RalBP1 was then puriﬁed by incubation
with Glutathione Sepharose™ 4B (Thermo Fisher Scientiﬁc) for 90min
on a roller, followed by 3× washes in lysis buﬀer, 1 x wash in high salt
buﬀer (0.5M NaCl, 0.1% Triton X-100) and resuspension in storage
buﬀer (1 x PBS, 50% glycerol, 1 mM DTT, 0.1% sodium azide).
2.4. Pulldown assay and immunoblotting
Following RBC8/vehicle treatment, human platelets at 4×108/mL
were stimulated, lysed and incubated with the GST-RalBP1 bait protein
to measure RalA/B activity and a GST-tagged Rap binding domain of
RalGDS (GST-RalGDS-RBD) bait to measure Rap1 activity [17,29].
Platelet lysate (30 μL) was retained from each sample as loading control
inputs. Pull-down and input samples were separated by electrophoresis
on 12% Tris-Glycine sodium dodecyl sulfate-polyacrylamide gels (SDS-
PAGE) and transferred to Immobilon-P membrane (Millipore, Hert-
fordshire, UK). Membranes were then blocked in 5% bovine serum al-
bumin (BSA – 1 h at RT) before incubation with primary (overnight at
4 °C) and secondary (1 h at RT) antibodies, with several washes in Tris-
buﬀered saline (TBS) containing 0.1% Tween in between. Immunoblots
were developed using an enhanced chemiluminescence (ECL) detection
system. Densitometry was performed with Image J (Version 1.46, NIH).
2.5. Lumi-aggregometry
Simultaneous assessment of platelet aggregation and dense granule
secretion (ATP release) was performed using a CHRONO-LOG® 700
lumi-aggregometer (Labmedics, Oxfordshire, UK) as previously de-
scribed [30].
2.6. Flow cytometry assays
To measure integrin activation and α-granule release, washed
human/mouse platelets were pre-incubated with 5 μL FITC-PAC1
(human)/PE-JON/A (mouse) and 2.5 μL PE (human)/FITC (mouse)-P-
selectin antibodies. Similarly, for phosphatidylserine exposure (PS)
analysis, washed human platelets were incubated with 2 μL Alexa Fluor
488-conjugated annexin V. Following RBC8/vehicle pretreatment,
samples were then stimulated with indicated concentrations of platelet
agonists for 10min at a ﬁnal platelet concentration of 2×107/mL in
the presence of 1mM CaCl2. Samples were analysed on an Accuri™ C6
Plus ﬂow cytometer (BD) with 10,000 gated events/sample.
2.7. Ex vivo thrombus formation
Analysis of human whole blood thrombus formation under ﬂowing
conditions was performed as previously described [31].
2.8. Platelet factor 4 (PF4) ELISA
Secretion of the α-granule protein, PF4, was measured using a
commercially available colorimetric ELISA kit. In brief, human washed
platelets (2× 108/mL) pretreated with RBC8/vehicle were recalciﬁed
with 1mM CaCl2 immediately prior to stimulation with indicated
concentrations of CRP for 10min at 37 °C. Platelets were then pelleted
(500 g for 2min) to isolate releasates, with a further 2 x pulse spins for
30 s to remove any debris. Control total samples were generated by
lysing platelets with an equal volume of 1% Triton X-100. Subsequent
ELISA steps were performed as per manufacturer's instructions with
releasate and total samples diluted 1/5000 and 1/10,000 in reagent
diluent (1% BSA in PBS), respectively. Absorbance values were de-
termined using a Tecan Inﬁnite® M200 Pro plate reader (Reading, UK).
2.9. Ca2+signalling
Human platelet rich plasma (PRP) isolated from whole blood was
incubated with 4 μM Fura-2 AM for 45min at 30 °C in the dark. Dye-
loaded washed platelets were allowed to recover and were then pre-
treated with RBC8/vehicle before been adjusted to 1×108/mL.
Samples were recalciﬁed with 1mM CaCl2 and analysed immediately
for basal Ca2+ values on a plate reader (10 cycles on a Tecan Inﬁnite®
M200 Pro), before the addition of CRP agonist. Changes in intracellular
Ca2+ were then monitored for 40 cycles (approximately 7.5min), with
area under the curve values generated for individual Ca2+ responses.
2.10. Platelet-leukocyte aggregates
Murine platelet-leukocyte aggregate formation was measured by
ﬂow cytometry as previously described [17].
2.11. Statistical analysis
Statistical analysis was performed using Graph Pad Prism 7 soft-
ware. All data are representative of a minimum of 3 independent ex-
periments, presented as mean ± standard deviation (s.d.). Statistical
diﬀerences were determined using one-way and two-way ANOVA with
Bonferroni's post hoc test. *P < 0.05 was considered statistically sig-
niﬁcant.
3. Results & discussion
Targeting speciﬁc signalling molecules in anucleate human platelets
is often hampered by the availability of selective pharmacological in-
hibitors. As a result, the ﬁeld of platelet biology is critically reliant on
studies using genetically modiﬁed mice or blood from patients with
inherited bleeding disorders due to mutations in genes regulating
haemostasis [32]. Our recent discovery in mouse platelets suggested a
critical role for the Ral GTPases, RalA and RalB, in regulating secretion
of P-selectin [17]. This ﬁnding opens therapeutic avenues for targeting
platelet-mediated inﬂammatory disorders requiring platelet expression
of P-selectin, and in our study we showed that platelet-speciﬁc deletion
of RalA and RalB signiﬁcantly slowed the onset of symptoms in a mouse
model of inﬂammatory bowel disease. We therefore set out to assess the
role of Rals in human platelets using the recently described Ral in-
hibitor RBC8 [26].
Initial experiments conﬁrmed that RBC8 eﬀectively inhibited both
RalA and RalB activation in an identical, dose-dependent manner fol-
lowing platelet stimulation with the GPVI-speciﬁc ligand, CRP (Fig.
1Ai). Non-speciﬁc, upper bands were observed when immunoblotting
for activated RalB, with the speciﬁc ‘GTP’ signal denoted by the arrow
(Fig. 1 Ai). The half-maximum inhibitory value (IC50) of RBC8 for RalA
and RalB was 2.2 μM and 2.3 μM, respectively (Fig. 1 Aii), which is
relatively similar to reported IC50 values of 3.5 and 3.4 μM in H2122
and H358 cells, respectively [26]. Having conﬁrmed the inhibitory ef-
fect of RBC8 on Ral activity, subsequent experiments set out to assess
the eﬀects of RBC8 treatment on platelet functional responses. We
speciﬁcally chose a threshold concentration of CRP (0.6 μg/mL) as we
had previously observed a relatively weak, but statistically signiﬁcant
reduction in dense granule secretion (ATP release), but not aggregation,
using this concentration in Ral DKO mouse platelets [17]. With this, we
observed a dose-dependent inhibitory eﬀect of RBC8 on human platelet
T.G. Walsh, et al. Cellular Signalling 59 (2019) 34–40
36
aggregation (Fig. 1B), with a concomitant decrease in dense granule
secretion (Fig. 1C). Secretion of ADP from platelet dense granules is an
important autocrine/paracrine signalling mediator of GPVI platelet
responses and we therefore used ADP “rescue” experiments with exo-
genously added ADP (10 μM) to understand the mechanism through
which RBC8 inhibits human platelet aggregation [33,34]. Notably,
exogenous ADP fully recovered the aggregation defect in the 1 and 3 μM
RBC8-treated platelet samples, but not completely in 10 μM RBC8
samples (Fig. 1B). This suggests that RBC8, particularly within the IC50
range (1–3 μM) reduces ADP secretion necessary for full aggregation
responses, but at the 10 μM dose there is an ADP-independent compo-
nent to RBC8-mediated reduction in platelet aggregation.
Previously, we established that genetic deletion of Rals in mouse
platelets causes a substantial reduction in P-selectin surface exposure,
without a signiﬁcant change in integrin αIIbβ3 activation [17]. Using
the same ﬂow cytometry assays, we investigated the eﬀect of RBC8 on
human platelet responses. Here, RBC8 signiﬁcantly decreased both
readouts of activation in human platelets and these reductions were not
agonist-dependent as signiﬁcant decreases were observed in response to
both CRP and PAR4-AP (Fig. 1D and E). While the reduction in P-se-
lectin exposure with RBC8 is consistent with responses in mouse Ral
DKO platelets, the decrease in integrin activation with RBC8 was a
noticeable divergence in functional responses between RBC8-treated
human platelets and mouse Ral DKO platelets. Similarly, we observed a
pronounced defect in thrombus formation in vitro in RBC8-treated
whole human blood perfused over a collagen-coated surface; a defect
which was not apparent in whole blood from Ral DKO mice (Fig. 1F).
However, considering the eﬀect of RBC8 on human platelet aggrega-
tion, granule secretion and integrin activation, it was not entirely un-
expected to observe defective platelet thrombus formation in RBC8-
Fig. 1. RBC8 inhibits RalA/B activity and speciﬁc functional responses in human platelets. (Ai) Washed platelets (4× 108/mL) pretreated with indicated con-
centrations of RBC8 were stimulated with CRP and monitored for RalA and RalB-GTP levels using GST-RalBP1 binding protein as bait, with loading controls for total
RalA/B content. The arrow is aligned with the RalB-GTP speciﬁc signal. (Aii) Densitometric analysis of RalA/B-GTP levels, normalised for total RalA/B loading, were
expressed relative to CRP-treated vehicle (0.2% DMSO), with IC50 calculation. (B and C) Washed platelets (2× 108/mL) pretreated with vehicle or RBC8 were
assessed for CRP (0.6 μg/mL)-induced aggregation (B) and dense granule secretion of ATP (C), +/− 10 μM ADP, using lumi-aggregometry. (D and E) Following
pretreatment with vehicle or RBC8, washed platelets (2× 107/mL) were activated with indicated concentrations of CRP or PAR4-AP for 10min and monitored for
integrin αIIbβ3 activation (D) and α-granule secretion (E) by PAC1 and P-selectin antibodies, respectively. (F) Anticoagulated whole blood, loaded with 2 μM DiOC6
was pre-treated with vehicle or RBC8 and perfused over collagen-coated surfaces at 1000s−1 for 6 min. Total platelet surface coverage (μm2) was calculated, with
representative confocal images (scale bar= 50 μm). (G) Washed platelets (2× 108/mL) pretreated with vehicle or RBC8 were stimulated with diﬀerent CRP con-
centrations and monitored for release of the α-granule protein, platelet factor 4 (PF4) by ELISA. Secreted PF4 values are expressed relative to total PF4 content from
lysed platelets. (H) Washed platelets (1× 108/mL) in platelet rich plasma (PRP) were loaded with 4 μM Fura-2 AM, pretreated with vehicle or RBC8 (concentration
indicated) and stimulated with indicated concentrations of CRP for 7.5 min. Results are displayed as area under the curve (AUC). (I) Changes in phosphatidylserine
(PS) exposure were monitored with Annexin V-488 binding in washed platelets (2×107/mL) pretreated with RBC and stimulated for 10min with CRP (5 μg/mL),
thrombin (1 U/mL) or combined CRP+ thrombin (5 μg/mL+1U/mL, respectively) in the presence of 1mM CaCl2. Data are mean ± s.d., n= 3 for (Aii, F, G and I),
n= 5 for (B and C), n= 6 for (D and E) and n= 4 for (H); *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. indicated sample; (ns) not signiﬁcant.
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treated whole blood [35]. This ﬁnding does also support the eﬃcacy of
using RBC8 in native environments such as whole blood, consistent
with the seminal paper by Yan et al. reporting decreases in tumor
growth from in vivo studies [26].
Further experiments in RBC8-treated human platelets assessed the
soluble release of the α-granule marker, PF4, Ca2+ mobilisation and
phosphatidylserine (PS) exposure (Fig. 1G–I). Here, platelet responses
following RBC8 treatment generally showed no eﬀect compared with
vehicle/DMSO-treated platelets. The lack of defect in PF4 secretion
with RBC8 treatment is important, and aligned with our observations in
Ral DKO mouse platelets that show a major defect in P selectin ex-
pression with no defect in PF4 release [17]. Furthermore, the absence of
altered Ca2+ signalling with RBC8 is consistent with previous reports
demonstrating that Ral activity is downstream of Ca2+ signalling, as an
increase in cytosolic Ca2+, either due to release from intracellular
stores and/or cellular inﬂux, is essential for Ral activation [7]. These
rises in cytosolic Ca2+ are also important for platelet procoagulant
function, as measured by annexin V binding to exposed PS, and
therefore the absence of altered PS responses with RBC8 is also un-
surprising [36]. Importantly, RBC8 did not alter basal/unstimulated
annexin V binding values in unstimulated platelets, conﬁrming that the
compound (between 1 and 10 μM) does not non-speciﬁcally induce
apoptosis in resting platelets (Fig. 1I).
Our observations with RBC8 in human platelets suggested a more
wide-ranging role for Rals in platelet function compared to our ob-
servations in Ral deﬁcient mouse platelets. Using lumi-aggregometry,
10 μM RBC8 signiﬁcantly reduced platelet aggregation and ATP secre-
tion responses in both WT and DKO platelets using the threshold con-
centration of CRP (0.6 μg/mL), while 3–10 μM RBC8 also signiﬁcantly
reduced ATP release (Fig. 2A and B). Further investigations using FACS
analysis to assess integrin activation (Fig. 2C) revealed almost identical,
dose-dependent reductions in both WT and Ral DKO platelets with
RBC8 treatment using either CRP or PAR4-AP as agonist. Here, in-
hibitory responses with RBC8 were more sensitive to lower (1 μM)
concentrations of compound compared to the aggregation/dense
granule secretion assay. The reduction in CRP-mediated P-selectin ex-
posure in WT platelets with RBC8 appeared to be dose-dependent, but
10 μM RBC8 was required to signiﬁcantly suppress P-selectin to levels
observed in Ral DKO platelets in the absence (or presence) of RBC8
(Fig. 2D). Furthermore, RBC8 could signiﬁcantly suppress WT platelet-
leukocyte aggregation formation, an eﬀect principally mediated by
platelet P-selectin interaction with PSGL-1 on leukocytes (Supplemen-
tary Fig. 1) [37]. We had previously demonstrated that Ral DKO pla-
telets have a near complete ablation of CRP-mediated platelet-leuko-
cyte interaction, making it challenging to determine oﬀ-target eﬀects of
RBC8 with this assay [17]. Using PAR4-AP as agonist, RBC8 appeared
less potent at reducing P-selectin levels in WT platelets, although 10 μM
RBC8 did signiﬁcantly decrease the response. However, 10 μM RBC8
did also signiﬁcantly suppress PAR4-AP-mediated P-selectin exposure
in Ral DKO platelets (Fig. 2D).
Overall, our data show that RBC8 elicits oﬀ-target eﬀects in mouse
platelets as evidenced by numerous inhibitory eﬀects in Ral DKO pla-
telets (Fig. 2A-D). It is therefore possible that similar oﬀ-target eﬀects
exist for RBC8 in human platelets, however we cannot deﬁnitively say
that this is the case since the diﬀerences in our data may just reﬂect
fundamental diﬀerences in Ral function between human and mouse
platelets. For instance, Rals may have a more critical role in regulating
human platelet dense secretion, as reported by Kawato et al., whereas
our observations in Ral deﬁcient mouse platelets suggest a very weak
role for Rals in dense granule release, which did not alter platelet ag-
gregation or integrin activation responses [16,17]. If such a diﬀerence
between species were true, it would help explain why inhibition of
human Rals (with RBC8) have a more profound eﬀect on human pla-
telet activation responses, which are critically reliant on secreted ADP
ampliﬁcation signals. Also, compensatory upregulation of speciﬁc sig-
nalling pathways have been previously reported in transgenic mice and
therefore it cannot be excluded that similar issues are present in Ral
DKO transgenic mice that could potentially mask Ral speciﬁc functions
in platelets [38]. However, even at 1 μM RBC8, which has weak in-
hibitory eﬀects on Ral activation (Fig. 1Aii, approximately 10% in-
hibition), we observed signiﬁcant eﬀects of the compound on CRP-
and/or PAR4-AP-induced human platelet integrin activation and P-se-
lectin exposure (Fig. 1D and E).
While our experiments suggest that RBC8 is targeting signalling
component(s) other than Rals in mouse platelets, it is not clear what
those target(s) are likely to be. In the Yan paper which identiﬁed RBC8
as a Ral inhibitor, the compound showed no oﬀ-target activity towards
Ras or RhoA, both of which are activated in response to platelet sti-
mulation [39,40]. The GTPase Rac1 has been shown to be important
speciﬁcally for GPVI-mediated platelet responses, but Rac1 deﬁcient
platelets have defective Ca2+ mobilisation and RBC8 did not alter CRP-
mediated Ca2+ signalling responses (Fig. 1H) [41]. Our observations
suggest the target(s) is likely to be a Ca2+ sensitive component of
platelet signalling pathways that is critical for integrin activation and
dense granule secretion, the latter being reinforced by our observations
that exogenous ADP could largely recover the platelet aggregation de-
fects with RBC8 treatment (Fig. 1B). Based on this, we suspected the
Rap1 isoforms, Rap1a and Rap1b, as likely candidates. Like Rals, they
are members of the Ras family of GTPases and are speciﬁcally regulated
by the calcium (and DAG) sensitive guanine nucleotide exchange factor
(GEF), CalDAG GEF1, and are critical regulators of integrin activation
and platelet secretory responses [6,42]. However, we did not observe
any inhibitory eﬀect of RBC8 (between 1 and 10 μM) on CRP-induced
Rap1 activation suggesting the oﬀ-target eﬀects are not mediated by
Rap1 (Supplementary Fig. 2). We are therefore currently uncertain of
the Ral-independent mechanism of RBC8 in platelets.
4. Conclusion
The development/discovery of compounds targeting small GTPases
is challenging [43,44]. Our data point to RBC8 being eﬃcient and
potent as a Ral inhibitor in human and mouse platelets, but that it
exhibits some activity beyond just Rals, particularly in mouse platelets.
It is however possible that species diﬀerences in Ral function and
structure could partly explain our observations in human platelets, in
which wider functions for Rals may be present than in mouse platelets.
For functional assessment of Rals in tissues it is advisable therefore to
use a combination of genetic and pharmacological approaches and to be
aware of possible species diﬀerences.
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